Life After Ebola: The Long-Term Effects on Survivors

Ebola is usually described by its death rate. More than 1,600 people have already recovered from the 2026 outbreak, and tens of thousands survived the 2014–16 epidemic — and for many of them the illness did not end at discharge. This page sets out what the research actually measured in survivors: which symptoms are genuinely more common than in people who were never infected, how the death rate changes in the first year, what "relapse" means, and the single long-term study of the Bundibugyo virus that is causing the current outbreak.

Sources: PREVAIL III (NEJM 2019), Clark et al. Lancet Infect Dis 2015, Mattia et al. Lancet Infect Dis 2016, Keita et al. Lancet Infect Dis 2019, Varkey et al. NEJM 2015, Jacobs et al. Lancet 2016, Keita et al. Nature 2021, WHO fact sheet. Last reviewed: November 1, 2026.

What Survivors Actually Have More Of

Lists of "post-Ebola syndrome" symptoms are easy to find. What most of them lack is a control group — and in the countries affected, headache, fatigue and joint pain are common in everyone. The study that fixed that is PREVAIL III.

The study. PREVAIL III, run by the Liberian Ministry of Health and the US National Institutes of Health, enrolled 966 antibody-positive survivors and 2,350 antibody-negative close contacts as controls, and followed 90% of them for a year. The first examination came a median of 358 days after the onset of illness (Sneller et al. for the PREVAIL III Study Group, N Engl J Med 2019). Everything in the table below is survivors versus people from the same households who were not infected.

Symptoms at about one year, survivors vs uninfected contacts

Source: PREVAIL III Study Group, NEJM 2019;380:924–34. The six symptoms are those reported significantly more often by survivors at enrollment; the difference column is our arithmetic on the published percentages. Survivors also more often had abnormal abdominal, chest, neurological and musculoskeletal findings on examination.
Reported symptom Survivors Contacts (controls) Difference
Joint pain47.5%17.5%+30 points
Memory loss29.2%4.8%+24 points (≈ 6×)
Muscle pain23.1%10.1%+13 points
Headache47.6%35.6%+12 points
Fatigue18.4%6.3%+12 points (≈ 3×)
Urinary frequency14.7%3.4%+11 points (≈ 4×)
Uveitis (on eye examination, enrollment)26.4%12.1%+14 points
Uveitis (at year 1)33.3%15.4%+18 points — rising

Two things the controls reveal

First, the background rate is high. More than a third of uninfected contacts reported headache and one in six reported joint pain. A survivor list that quotes "47% have headaches" without that comparison overstates what Ebola did; the honest figure is a 12-point excess. Memory loss is the opposite case — 29% against 5% is a difference the disease clearly owns.

Second, most of it gets better, and one thing does not. In PREVAIL III (NEJM 2019) the prevalence of the symptoms and examination findings declined over the year of follow-up in both groups — with the exception of uveitis, which rose in survivors from 26.4% to 33.3%. The incidence of new symptoms, new neurological findings and new uveitis over the year was also higher in survivors. The eye is the organ in which the disease keeps going after the patient feels recovered, which is why it has its own section below.

The same study found Ebola RNA in the semen of 30% of survivors tested, with a maximum interval of 40 months from illness to detection — the persistence data are on our transmission page and are not repeated here.

The Eye: Where the Virus Hides and the Sight-Threatening Complication

The reason uveitis behaves differently from every other sequela was found in one patient. Ian Crozier, an American physician infected in Sierra Leone and treated at Emory University Hospital in 2014, developed severe uveitis in one eye during convalescence. Viable Ebola virus was recovered from the aqueous humor — the fluid inside the eye — 14 weeks after his illness began and 9 weeks after his blood had cleared (Varkey et al., N Engl J Med 2015). The eye is an immune-privileged site; the virus survives there after the rest of the body has cleared it, and the inflammation that follows is the uveitis.

How common it is in the field was measured at the survivor clinic in Port Loko, Sierra Leone, which cared for 603 of the district's 661 survivors. Among 277 seen in spring 2015, a median of 121 days after discharge: arthralgia in 76%, new eye symptoms in 60%, uveitis on examination in 18%, and auditory symptoms in 24% (Mattia et al., Lancet Infect Dis 2016). The strongest predictor of uveitis was how much virus the patient had carried during acute illness — for every five-point drop in the PCR cycle threshold (that is, each roughly 30-fold rise in viral load) the adjusted odds of uveitis rose 3.33-fold. Sicker patients, more eye disease.

Why this matters for care. Uveitis is treatable and, untreated, can cause cataract, glaucoma and blindness. Mattia and colleagues called the sequelae "sometimes sight threatening" and called for "urgent provision of ocular care" as part of survivor follow-up. An eye examination is the single highest-yield item in a survivor clinic — which is a resource question in the places that have the survivors.

The First Year: A Five-Fold Death Rate That Then Disappears

Surviving the treatment unit is not the end of the risk. Guinea's national survivor monitoring programme attempted to trace every person discharged from an Ebola treatment unit during the 2013–16 epidemic and retrieved information on 1,130 of 1,270 (89%) (Keita et al., Lancet Infect Dis 2019). Its findings:

  • Over roughly the first year after discharge, survivors had a more than five-fold increased risk of death compared with the general Guinean population — an age-standardised mortality ratio of 5.2 (95% CI 4.0–6.8).
  • From January to September 2016 — the second year — the excess was gone: standardised mortality ratio 0.6 (95% CI 0.2–1.4), no different from the general population.
  • Of 59 deaths recorded, 37 were tentatively attributed to renal failure, mostly on the basis of family reports that the person had stopped passing urine. The authors flagged the role of kidney failure in late deaths as needing investigation.
  • People whose original stay in the treatment unit was at or above the median length had 2.62 times the risk of late death (adjusted hazard ratio, 95% CI 1.43–4.79) — the survivors who were sickest first are the ones to watch.

Read with the PREVAIL III trajectory — most symptoms declining over the first year, the eye the exception — the picture is of a disease whose after-effects are front-loaded. The dangerous window is the first twelve months, and the people at most risk in it are identifiable from their original hospital course.

Persistence and Relapse: Rare, Documented, and the Reason Survivor Programmes Exist

WHO's fact sheet states the position plainly: orthoebolaviruses "are known to persist in immune-privileged sites in some people who have recovered" — the testicles, the inside of the eye and the brain — and "relapse-symptomatic illness in the absence of re-infection in someone who has recovered from Ebola disease is rare but has been documented. Reasons for this phenomenon are not yet fully understood." Three cases define what that means.

CDC's outbreak history likewise attributes all three 2021 outbreaks (Guinea and two in DRC) to persistent infection in survivors rather than to new spillovers. The 2016 Guinea–Liberia cluster from one survivor's seminal virus about 470 days after his illness is on our transmission page.
EventWhenWhat it established
Virus in the eye — Crozier, treated at Emory 14 weeks after onset; 9 weeks after the blood cleared Live virus survives in the eye after recovery and causes uveitis (Varkey et al., NEJM 2015)
Late relapse with meningoencephalitis — a Scottish nurse who had worked in Sierra Leone Readmitted 9 months after discharge with undetectable blood RNA at discharge First documented life-threatening relapse: Ebola virus in the cerebrospinal fluid; treated with supportive care and experimental antivirals; she survived (Jacobs et al., Lancet 2016)
An outbreak seeded by a survivor — Guinea, 2021 About five years after the 2013–16 epidemic ended Genome sequencing of 12 patients showed the 2021 viruses clustered with the earlier outbreak and had diverged far less than years of human-to-human spread would produce — "a persistent infection with reduced replication or a period of latency", not a new animal spillover (Keita et al., Nature 2021)

These are single events against thousands of survivors, and the Nature authors drew the humane conclusion rather than the alarmist one: the resurgence "reinforces the need for long-term medical and social care for patients who survive the disease, to reduce the risk of re-emergence and to prevent further stigmatization." A survivor is a person who needs follow-up, not a threat to be shunned — and WHO's guidance says so directly: it "does not recommend isolation of recovered patients whose blood has tested negative", and "all survivors, their partners and families should be shown respect, dignity and compassion."

Mind and Community

The physical sequelae come with a psychological burden that the biomedical literature measured late. A meta-analysis of 13 studies of survivors of the 2014–16 West African epidemic pooled the prevalence of anxiety at 14%, depression at 15% and insomnia at 22% (Acharibasam et al., PLoS One 2021) — figures the authors called moderate to high, against a background in which survivors had often lost family members to the same outbreak, lost livelihoods during isolation, and returned to communities that feared them. The memory-loss finding in PREVAIL III (29% vs 5%) and the confusion-related limitations reported by Bundibugyo survivors (below) sit somewhere between the neurological and the psychological, and the studies cannot fully separate them.

WHO's fact sheet lists the response: "care programmes to alleviate sequelae, support to community reintegration, counselling and biological testing." Stigma is not a footnote to survivor care; the Nature authors named preventing it as one of the two reasons long-term care matters.

The Bundibugyo Evidence — the Species Behind the 2026 Outbreak

Nearly everything above concerns Zaire virus, because that is what the 2014–16 epidemic was. The 2026 DRC outbreak is Bundibugyo virus. There is exactly one long-term study of its survivors.

After the 2007 Bundibugyo outbreak in western Uganda, a US Army–Makerere University team invited survivors and their contacts to an observational study about 29 months later, and analysed 49 probable and confirmed survivors against 157 seronegative contacts (Clark et al., Lancet Infect Dis 2015). Controlling for age and sex, survivors were at significantly increased risk of:

Source: Clark et al., Lancet Infect Dis 2015;15:905–12. Small study; the wide interval on the memory-loss finding reflects that. The authors' conclusion: "long-term sequelae persist for more than 2 years after Ebola virus disease."
FindingRelative risk (95% CI)
Retro-orbital pain (pain behind the eyes)4.3 (1.9–9.6)
Hearing loss2.3 (1.2–4.5)
Difficulty swallowing2.1 (1.1–3.9)
Joint pain2.0 (1.1–3.6)
Blurred vision1.9 (1.1–3.2)
Difficulty sleeping1.9 (1.3–2.8)
Chronic health problems (prevalence ratio)2.1 (1.2–3.6)
Limitations due to memory loss or confusion (prevalence ratio)5.8 (1.5–22.4)

The pattern — eyes, joints, hearing, sleep, memory — is the same one PREVAIL III and the Sierra Leone clinic later documented after Zaire virus, and it was visible in Bundibugyo survivors more than two years on. With WHO reporting more than 1,600 people recovered from the 2026 outbreak by early September (DON 617), that is the evidence base the DRC survivor programme has to work from. What it does not yet have is any measurement of how long Bundibugyo virus persists in survivors' semen or eyes; every persistence cohort above studied Zaire virus. That gap is listed on our transmission page as an open question the 2026 outbreak will be the first able to answer.

Frequently Asked Questions

What are the long-term effects of Ebola?

Against uninfected controls a year on, PREVAIL III (NEJM 2019) found excess joint pain (47.5% vs 17.5%), headache (47.6% vs 35.6%), memory loss (29.2% vs 4.8%), muscle pain (23.1% vs 10.1%), fatigue (18.4% vs 6.3%) and urinary frequency (14.7% vs 3.4%), plus uveitis (26.4% vs 12.1%, rising to 33.3% at a year). Most declined over time; the eye disease did not. Add a five-fold death rate in the first year after discharge and a measurable burden of anxiety, depression and insomnia.

Can Ebola come back after recovery?

Rarely. WHO: relapse without re-infection "is rare but has been documented". The virus persists in the testicles, eye and brain. A Scottish nurse relapsed with meningitis nine months after discharge; the 2021 Guinea outbreak was sequenced back to a survivor about five years after the previous epidemic. Exceptional events against thousands of survivors — and the reason survivor care and semen testing exist.

Why the eyes?

Because live virus survives inside the eye after the blood is clear — recovered from one patient's aqueous humor 14 weeks after onset — and the immune response to it is uveitis. In Port Loko, 18% of survivors had uveitis and 60% new eye symptoms, with risk rising with acute viral load. It can threaten sight and is treatable, which is why eye examination is the priority in survivor clinics.

Are survivors more likely to die later?

In the first year, yes: an age-standardised mortality ratio of 5.2 in Guinea's national cohort of 1,130 traced survivors, then no excess in the second year. Most late deaths were tentatively attributed to kidney failure, and a longer original hospital stay carried 2.62 times the risk.

What about Bundibugyo survivors — the 2026 species?

One study: 49 survivors of Uganda's 2007 outbreak against 157 contacts, 29 months later. Significantly raised risk of retro-orbital pain (4.3×), hearing loss (2.3×), difficulty swallowing (2.1×), joint pain (2.0×), blurred vision (1.9×), poor sleep (1.9×), chronic health problems (2.1×) and memory-related limitation (5.8×). The same pattern as Zaire virus, more than two years on. Nothing is yet known about Bundibugyo persistence in semen or eyes.

Is a survivor contagious?

Not through everyday contact — WHO does not recommend isolating recovered patients with negative blood tests. Semen is the exception: virus persisted in 62% of men at 4–6 months and 4% at 16–18 months in one cohort, with sexual transmission documented up to fifteen months after recovery. WHO advises monthly semen testing until two negatives, or safer sex for 12 months. Full data on the transmission page.

This page summarises peer-reviewed survivor studies and WHO guidance. It is not medical advice and not a substitute for the survivor-care programme or clinician looking after a specific person; symptoms after Ebola — especially eye pain or vision change — need prompt clinical assessment.

Sources & References

  1. PREVAIL III Study Group; Sneller MC, Reilly C, Badio M, et al. A longitudinal study of Ebola sequelae in Liberia. N Engl J Med 2019;380(10):924–34 — 966 survivors vs 2,350 contacts; the six excess symptoms; uveitis 26.4% vs 12.1% rising to 33.3% vs 15.4%; semen RNA in 30%, maximum 40 months. doi:10.1056/NEJMoa1805435
  2. Clark DV, Kibuuka H, Millard M, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis 2015;15(8):905–12 — 49 survivors vs 157 contacts at ~29 months; relative risks as tabulated. doi:10.1016/S1473-3099(15)70152-0
  3. Mattia JG, Vandy MJ, Chang JC, et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis 2016;16(3):331–8 — 277 survivors, median 121 days post-discharge: arthralgia 76%, new ocular symptoms 60%, uveitis 18%, auditory symptoms 24%; uveitis aOR 3.33 per 5-point Ct decrease. doi:10.1016/S1473-3099(15)00489-2
  4. Keita M, Diallo B, Mesfin S, et al. Subsequent mortality in survivors of Ebola virus disease in Guinea: a nationwide retrospective cohort study. Lancet Infect Dis 2019;19(11):1202–8 — 1,130 of 1,270 survivors traced; SMR 5.2 (4.0–6.8) in the first year, 0.6 (0.2–1.4) thereafter; 37 of 59 deaths attributed to renal failure; aHR 2.62 for longer initial stay. doi:10.1016/S1473-3099(19)30313-5
  5. Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 2015;372(25):2423–7 — viable virus in aqueous humor 14 weeks after onset, 9 weeks after viremia cleared. doi:10.1056/NEJMoa1500306
  6. Jacobs M, Rodger A, Bell DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 2016;388(10043):498–503 — readmission 9 months after discharge; virus in CSF. doi:10.1016/S0140-6736(16)30386-5
  7. Keita AK, Koundouno FR, Faye M, et al. Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. Nature 2021;597(7877):539–43 — 2021 genomes cluster with the 2013–16 outbreak with far lower divergence than sustained transmission would produce; resurgence from a human source about five years later. doi:10.1038/s41586-021-03901-9
  8. Acharibasam JW, Chireh B, Menegesha HG. Assessing anxiety, depression and insomnia symptoms among Ebola survivors in Africa: a meta-analysis. PLoS One 2021;16(2):e0246515 — 13 studies; pooled anxiety 14%, depression 15%, insomnia 22%. doi:10.1371/journal.pone.0246515
  9. Deen GF, et al. Ebola RNA persistence in semen of Ebola virus disease survivors — final report. N Engl J Med 2017;377:1428–37 — the 62% at 4–6 months and 4% at 16–18 months figures quoted in the FAQ. doi:10.1056/NEJMoa1511410
  10. World Health Organization. Ebola disease fact sheet — care for survivors, persistence in immune-privileged sites, relapse "rare but has been documented", transmission via semen up to fifteen months, semen-testing programme, persistence in breast milk, placenta and amniotic fluid. who.int/news-room/fact-sheets/detail/ebola-virus-disease
  11. World Health Organization. Disease Outbreak News 617 (September 10, 2026): Ebola disease caused by Bundibugyo virus — Democratic Republic of the Congo — more than 1,600 recovered patients. who.int/…/2026-DON617
  12. Centers for Disease Control and Prevention. History of Ebola Outbreaks (reviewed May 29, 2026) — the 2021 Guinea and DRC outbreaks linked to persistent infection in survivors. cdc.gov/ebola/outbreaks